Prognostic Impacts of Hypoxic Markers in Soft Tissue Sarcoma

Background. We aimed to explore the prognostic impact of the hypoxia-induced factors (HIFαs) 1 and 2, the metabolic HIF-regulated glucose transporter GLUT-1, and carbonic anhydrase IX (CAIX) in non-gastrointestinal stromal tumor soft tissue sarcomas (non-GIST STS). Methods. Duplicate cores with viable tumor tissue from 206 patients with non-GIST STS were obtained and tissue microarrays were constructed. Immunohistochemistry (IHC) was used to evaluate expression of hypoxic markers. Results. In univariate analyses, GLUT-1 (P < 0.001) and HIF-2α (P = 0.032) expression correlated significantly with a poor disease-specific survival (DSS). In the multivariate analysis, however, only high expression of GLUT-1 (HR 1.7, CI 95% 1.1–2.7, P = 0.021) was a significant independent prognostic indicator of poor DSS. Conclusion. GLUT-1 is a significant independent negative prognostic factor in non-GIST STS.

[1]  K. Milde-Langosch,et al.  Carbonic anhydrase IX in tumor tissue and sera of patients with primary cervical cancer , 2011, BMC Cancer.

[2]  T. Dønnem,et al.  Profiling of VEGFs and VEGFRs as Prognostic Factors in Soft Tissue Sarcoma: VEGFR-3 Is an Independent Predictor of Poor Prognosis , 2010, PloS one.

[3]  J. Blay,et al.  Perspective on updated treatment guidelines for patients with gastrointestinal stromal tumors , 2010, Cancer.

[4]  J. Overgaard,et al.  Identifying hypoxia in human tumors: A correlation study between 18F-FMISO PET and the Eppendorf oxygen-sensitive electrode , 2010, Acta oncologica.

[5]  Bo Zhang,et al.  HIF-1α and HIF-2α correlate with migration and invasion in gastric cancer , 2010, Cancer biology & therapy.

[6]  J. Pouysségur,et al.  High levels of carbonic anhydrase IX in tumour tissue and plasma are biomarkers of poor prognostic in patients with non-small cell lung cancer , 2010, British Journal of Cancer.

[7]  W. Carney,et al.  Serum carbonic anhydrase IX during first-line therapy of ovarian cancer. , 2010, Gynecologic oncology.

[8]  P. Hogendoorn,et al.  Correlation of hypoxic signalling to histological grade and outcome in cartilage tumours , 2010, Histopathology.

[9]  N. Umesaki,et al.  Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas. , 2010, Oncology reports.

[10]  G. Semenza.  Defining the role of hypoxia-inducible factor 1 in cancer biology and therapeutics , 2010, Oncogene.

[11]  H. Taubert,et al.  Co-expression of Hif1alpha and CAIX is associated with poor prognosis in oral squamous cell carcinoma patients. , 2009, Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology.

[12]  A. Jemal,et al.  Cancer Statistics, 2009 , 2009, CA: a cancer journal for clinicians.

[13]  W. Travis,et al.  Glucose transporter-1 in pulmonary neuroendocrine carcinomas: expression and survival analysis , 2009, Modern Pathology.

[14]  M. Lerman,et al.  Transcriptional control of the tumor- and hypoxia-marker carbonic anhydrase 9: A one transcription factor (HIF-1) show? , 2009, Biochimica et biophysica acta.

[15]  G. Semenza,et al.  Regulation of cancer cell metabolism by hypoxia-inducible factor 1. , 2009, Seminars in cancer biology.

[16]  A. Folpe,et al.  GLUT-1 expression in mesenchymal tumors: an immunohistochemical study of 247 soft tissue and bone neoplasms. , 2008, Human pathology.

[17]  J. Shay,et al.  In vivo and in vitro effects of a HIF‐1α inhibitor, RX‐0047 , 2008, Journal of cellular biochemistry.

[18]  U. Tateishi,et al.  Prognostic implications of glucose transporter protein-1 (glut-1) overexpression in bone and soft-tissue sarcomas. , 2007, Japanese journal of clinical oncology.

[19]  J. Pouysségur,et al.  Hypoxia and cancer , 2007, Journal of Molecular Medicine.

[20]  T. Dønnem,et al.  Inverse Prognostic Impact of Angiogenic Marker Expression in Tumor Cells versus Stromal Cells in Non–Small Cell Lung Cancer , 2007, Clinical Cancer Research.

[21]  J. Cheville,et al.  Carbonic anhydrase IX is not an independent predictor of outcome for patients with clear cell renal cell carcinoma. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  G. Semenza.  Evaluation of HIF-1 inhibitors as anticancer agents. , 2007, Drug discovery today.

[23]  Jun Suk Kim,et al.  Glucose transporter-1 expression in squamous cell carcinoma of the tongue. , 2007, Cancer research and treatment : official journal of Korean Cancer Association.

[24]  A. Uchida,et al.  Expression of hypoxia-inducible factor (HIF)-1α as a biomarker of outcome in soft-tissue sarcomas , 2006, Virchows Archiv.

[25]  C. Supuran,et al.  Targeting tumor-associated carbonic anhydrase IX in cancer therapy. , 2006, Trends in pharmacological sciences.

[26]  S. Hahn,et al.  Nelfinavir down-regulates hypoxia-inducible factor 1alpha and VEGF expression and increases tumor oxygenation: implications for radiotherapy. , 2006, Cancer research.

[27]  Qi Fang Li,et al.  Hypoxia upregulates hypoxia inducible factor (HIF)-3α expression in lung epithelial cells: characterization and comparison with HIF-1α , 2006, Cell Research.

[28]  J. Pouysségur,et al.  Hypoxia signalling in cancer and approaches to enforce tumour regression , 2006, Nature.

[29]  E. Stanbridge,et al.  Comparison between pimonidazole binding, oxygen electrode measurements, and expression of endogenous hypoxia markers in cancer of the uterine cervix , 2006, Cytometry. Part B, Clinical cytometry.

[30]  U. Tateishi,et al.  Glut-1 expression and enhanced glucose metabolism are associated with tumour grade in bone and soft tissue sarcomas: a prospective evaluation by [18F]fluorodeoxyglucose positron emission tomography , 2006, European Journal of Nuclear Medicine and Molecular Imaging.

[31]  A. Harris,et al.  Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 alpha and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. , 2006, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[32]  C. Fletcher.  The evolving classification of soft tissue tumours: an update based on the new WHO classification , 2006, Histopathology.

[33]  R. Airley,et al.  Hypoxia-regulated glucose transporter Glut-1 may influence chemosensitivity to some alkylating agents: results of EORTC (First Translational Award) study of the relevance of tumour hypoxia to the outcome of chemotherapy in human tumour-derived xenografts. , 2005, International journal of oncology.

[34]  M. Tachibana,et al.  Prognostic Impact of Hypoxia-Inducible Factors 1α and 2α in Colorectal Cancer Patients , 2004, Clinical Cancer Research.

[35]  M. Matthay,et al.  Prolonged Hypoxia Differentially Regulates Hypoxia-inducible Factor (HIF)-1α and HIF-2α Expression in Lung Epithelial Cells , 2004, Journal of Biological Chemistry.

[36]  O. Jöhren,et al.  Hypoxia rapidly activates HIF‐3α mRNA expression , 2003 .

[37]  Peter Bartenstein,et al.  Overexpression of Glut‐1 and increased glucose metabolism in tumors are associated with a poor prognosis in patients with oral squamous cell carcinoma , 2003, Cancer.

[38]  Toru Suzuki,et al.  Endothelial PAS Domain Protein 1 (EPAS1) Regulates the Fit-1 Gene Expression in Hypoxia , 2002 .

[39]  R. Angioli,et al.  GLUT‐1 expression in ovarian carcinoma , 2001, Cancer.

[40]  A. Harris,et al.  Relation of hypoxia inducible factor 1α and 2α in operable non-small cell lung cancer to angiogenic/molecular profile of tumours and survival , 2001, British Journal of Cancer.

[41]  M. Welch,et al.  PET imaging of hypoxia. , 2001, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

[42]  O. Kallioniemi,et al.  Tissue microarray technology for high-throughput molecular profiling of cancer. , 2001, Human molecular genetics.

[43]  Y. Kaneda,et al.  Sp1 decoy transfected to carcinoma cells suppresses the expression of vascular endothelial growth factor, transforming growth factor beta1, and tissue factor and also cell growth and invasion activities. , 2000, Cancer research.

[44]  D A Hilton,et al.  Overexpression of hypoxia-inducible factor 1alpha in common human cancers and their metastases. , 1999, Cancer research.

[45]  D. Burstein,et al.  GLUT1 glucose transporter expression in colorectal carcinoma , 1998, Cancer.

[46]  Mark A. Stephenson,et al.  Overexpression of glut1 and glut3 in stage I nonsmall cell lung carcinoma is Associated with poor survival , 1997, Cancer.

[47]  Y Fujii-Kuriyama,et al.  A novel bHLH-PAS factor with close sequence similarity to hypoxia-inducible factor 1alpha regulates the VEGF expression and is potentially involved in lung and vascular development. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[48]  P Vaupel,et al.  Association between tumor hypoxia and malignant progression in advanced cancer of the uterine cervix. , 1996, Cancer research.

[49]  O. S. Nielsen,et al.  The relationship between tumor oxygenation and cell proliferation in human soft tissue sarcomas. , 1996, International journal of radiation oncology, biology, physics.

[50]  M. Dewhirst,et al.  Tumor oxygenation predicts for the likelihood of distant metastases in human soft tissue sarcoma. , 1996, Cancer research.

[51]  M. Younes,et al.  Wide expression of the human erythrocyte glucose transporter Glut1 in human cancers. , 1996, Cancer research.

[52]  G. Semenza,et al.  A nuclear factor induced by hypoxia via de novo protein synthesis binds to the human erythropoietin gene enhancer at a site required for transcriptional activation , 1992, Molecular and cellular biology.

[53]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[54]  W. Marsden.  I and J , 2012 .

[55]  永松 晃.  Use of 18F-fluorodeoxyglucose positron emission tomography for diagnosis of uterine sarcomas , 2010 .

[56]  J. Pouysségur,et al.  Hypoxia-inducible carbonic anhydrase IX and XII promote tumor cell growth by counteracting acidosis through the regulation of the intracellular pH. , 2009, Cancer research.

[57]  M. Welch,et al.  Positron Emission Tomography Imaging of Hypoxia. , 2009, PET clinics.

[58]  Michael Höckel,et al.  Endogenous hypoxia markers: case not proven! , 2008, Advances in experimental medicine and biology.

[59]  Iroon Polytechniou.  Influence of cultivation temperature on the ligninolytic activity of selected fungal strains , 2006 .

[60]  O. Jöhren,et al.  Hypoxia rapidly activates HIF-3alpha mRNA expression. , 2003, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[61]  L. Wartman,et al.  Molecular characterization and chromosomal localization of a third alpha-class hypoxia inducible factor subunit, HIF3alpha. , 1998, Gene expression.

[62]  F. Collin,et al.  Comparative study of the National Cancer Institute and French Federation of Cancer Centers Sarcoma Group grading systems in a population of 410 adult patients with soft tissue sarcoma. , 1997, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[63]  S. McKnight,et al.  Endothelial PAS domain protein 1 (EPAS1), a transcription factor selectively expressed in endothelial cells. , 1997, Genes & development.

[64]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.